去势抵抗性前列腺癌-话题@MedSci

#去势抵抗性前列腺癌#

112篇内容 | 2944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1342170, encodeId=1fbc13421e03b, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=89, createdTime=2021-07-31, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342169, encodeId=dd85134216993, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系, objectType=article, longId=213835, objectId=38ec21383567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38ec21383567, replyNumber=0, likeNumber=73, createdTime=2021-07-08, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38ec21383567, moduleTitle=JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38ec21383567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342168, encodeId=1715134216801, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , objectType=article, longId=213257, objectId=9d5921325e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5921325e93, replyNumber=0, likeNumber=0, createdTime=2021-06-27, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5921325e93, moduleTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d5921325e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342167, encodeId=64ce134216e90, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌, objectType=article, longId=213197, objectId=2d2e21319ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d2e21319ed9, replyNumber=0, likeNumber=71, createdTime=2021-06-26, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2e21319ed9, moduleTitle=NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2e21319ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342166, encodeId=d91113421660d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=World J Urol：miR-3195、miR-3687和miR-4417的上调与去势抵抗性前列腺癌相关, objectType=article, longId=211930, objectId=1d8b2119305b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d8b2119305b, replyNumber=0, likeNumber=93, createdTime=2021-05-29, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d8b2119305b, moduleTitle=World J Urol：miR-3195、miR-3687和miR-4417的上调与去势抵抗性前列腺癌相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d8b2119305b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342165, encodeId=70bf1342165e2, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物 , objectType=article, longId=210647, objectId=bb1d21064eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb1d21064eea, replyNumber=0, likeNumber=84, createdTime=2021-05-01, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb1d21064eea, moduleTitle=Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb1d21064eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342164, encodeId=6803134216428, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量 , objectType=article, longId=210272, objectId=e8832102e21a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8832102e21a, replyNumber=0, likeNumber=0, createdTime=2021-04-23, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8832102e21a, moduleTitle=Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8832102e21a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342163, encodeId=85aa13421636f, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , objectType=article, longId=209040, objectId=19e420904055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e420904055, replyNumber=0, likeNumber=75, createdTime=2021-03-28, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e420904055, moduleTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19e420904055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342162, encodeId=0686134216242, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能, objectType=article, longId=209038, objectId=d71e2090385c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71e2090385c, replyNumber=0, likeNumber=0, createdTime=2021-03-28, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71e2090385c, moduleTitle=Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71e2090385c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342161, encodeId=44fa1342161b4, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, objectType=article, longId=208515, objectId=d0982085157d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0982085157d, replyNumber=0, likeNumber=70, createdTime=2021-03-18, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0982085157d, moduleTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0982085157d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342160, encodeId=6717134216037, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Nat Med：转移性去势抵抗性前列腺癌治疗耐药性的相关研究, objectType=article, longId=208287, objectId=e5a220828e80, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a220828e80, replyNumber=0, likeNumber=0, createdTime=2021-03-13, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a220828e80, moduleTitle=Nat Med：转移性去势抵抗性前列腺癌治疗耐药性的相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a220828e80)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342159, encodeId=5396134215952, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, objectType=article, longId=207265, objectId=388d20e265f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=388d20e265f5, replyNumber=0, likeNumber=0, createdTime=2021-02-20, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=388d20e265f5, moduleTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=388d20e265f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342158, encodeId=19a91342158ae, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, objectType=article, longId=207230, objectId=677220e230b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677220e230b0, replyNumber=0, likeNumber=61, createdTime=2021-02-19, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677220e230b0, moduleTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=677220e230b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342157, encodeId=6823134215e5e, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=64, createdTime=2021-02-11, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342156, encodeId=40b3134215653, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Clin Cancer Res：PSMA靶向AMG160疗法在转移去势抵抗性前列腺癌临床前模型中具有强效的抗肿瘤活性, objectType=article, longId=206884, objectId=a7cd206884c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7cd206884c6, replyNumber=0, likeNumber=83, createdTime=2021-02-08, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7cd206884c6, moduleTitle=Clin Cancer Res：PSMA靶向AMG160疗法在转移去势抵抗性前列腺癌临床前模型中具有强效的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7cd206884c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342155, encodeId=20da134215589, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur J Cancer：双极雄激素治疗使去势抵抗性前列腺癌对后续的雄激素受体消融治疗敏感 , objectType=article, longId=205676, objectId=e1a22056e615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1a22056e615, replyNumber=0, likeNumber=65, createdTime=2021-01-14, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1a22056e615, moduleTitle=Eur J Cancer：双极雄激素治疗使去势抵抗性前列腺癌对后续的雄激素受体消融治疗敏感 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1a22056e615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342154, encodeId=2afb134215437, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, objectType=article, longId=205674, objectId=19872056e42f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19872056e42f, replyNumber=0, likeNumber=87, createdTime=2021-01-14, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19872056e42f, moduleTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19872056e42f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342153, encodeId=5c521342153aa, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Br J Cancer：LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展, objectType=article, longId=204968, objectId=992d204968b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=992d204968b4, replyNumber=0, likeNumber=65, createdTime=2020-12-30, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=992d204968b4, moduleTitle=Br J Cancer：LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=992d204968b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342152, encodeId=b7f51342152a7, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, objectType=article, longId=204950, objectId=4b6d204950d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b6d204950d0, replyNumber=0, likeNumber=77, createdTime=2020-12-30, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b6d204950d0, moduleTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b6d204950d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342151, encodeId=a1261342151fa, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , objectType=article, longId=204687, objectId=679620468e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679620468e97, replyNumber=0, likeNumber=57, createdTime=2020-12-21, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679620468e97, moduleTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679620468e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

去势抵抗性前列腺癌

2020-05-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2021-07-31

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

JAMA Netw Open：化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系

2021-07-08

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系

2021-06-27

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

NEJM：177Lu-PSMA-617靶向放疗治疗PSMA阳性转移性去势抵抗性前列腺癌

2021-06-26

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

World J Urol：miR-3195、miR-3687和miR-4417的上调与去势抵抗性前列腺癌相关

2021-05-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Sci Rep：用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物

2021-05-01

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer P D：恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量

2021-04-23

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果

2021-03-28

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Oncogene：核βArrestin1能够调控去势抵抗性前列腺癌的雄激素受体功能

2021-03-28

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验

2021-03-18

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Nat Med：转移性去势抵抗性前列腺癌治疗耐药性的相关研究

2021-03-13

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析

2021-02-20

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）

2021-02-19

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-02-11

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Clin Cancer Res：PSMA靶向AMG160疗法在转移去势抵抗性前列腺癌临床前模型中具有强效的抗肿瘤活性

2021-02-08

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur J Cancer：双极雄激素治疗使去势抵抗性前列腺癌对后续的雄激素受体消融治疗敏感

2021-01-14

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究

2021-01-14

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Br J Cancer：LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展

2020-12-30

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌

2020-12-30

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

2020-12-21

科室
- - 订阅+
  - 更多科室
工具
服务